Cargando…

Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites

BACKGROUND: A primary concern when targeting HIV-1 RNA by means of antisense related technologies is the accessibility of the targets. Using a library selection approach to define the most accessible sites for 20-mer oligonucleotides annealing within the highly structured 5'-UTR of the HIV-1 ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobsen, Martin R, Haasnoot, Joost, Wengel, Jesper, Berkhout, Ben, Kjems, Jørgen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1866241/
https://www.ncbi.nlm.nih.gov/pubmed/17459171
http://dx.doi.org/10.1186/1742-4690-4-29
_version_ 1782133254218842112
author Jakobsen, Martin R
Haasnoot, Joost
Wengel, Jesper
Berkhout, Ben
Kjems, Jørgen
author_facet Jakobsen, Martin R
Haasnoot, Joost
Wengel, Jesper
Berkhout, Ben
Kjems, Jørgen
author_sort Jakobsen, Martin R
collection PubMed
description BACKGROUND: A primary concern when targeting HIV-1 RNA by means of antisense related technologies is the accessibility of the targets. Using a library selection approach to define the most accessible sites for 20-mer oligonucleotides annealing within the highly structured 5'-UTR of the HIV-1 genome we have shown that there are at least four optimal targets available. RESULTS: The biological effect of antisense DNA and LNA oligonucleotides, DNA- and LNAzymes targeted to the four most accessible sites was tested for their abilities to block reverse transcription and dimerization of the HIV-1 RNA template in vitro, and to suppress HIV-1 production in cell culture. The neutralization of HIV-1 expression declined in the following order: antisense LNA > LNAzymes > DNAzymes and antisense DNA. The LNA modifications strongly enhanced the in vivo inhibitory activity of all the antisense constructs and some of the DNAzymes. Notably, two of the LNA modified antisense oligonucleotides inhibited HIV-1 production in cell culture very efficiently at concentration as low as 4 nM. CONCLUSION: LNAs targeted to experimentally selected binding sites can function as very potent inhibitors of HIV-1 expression in cell culture and may potentially be developed as antiviral drug in patients.
format Text
id pubmed-1866241
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18662412007-05-09 Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites Jakobsen, Martin R Haasnoot, Joost Wengel, Jesper Berkhout, Ben Kjems, Jørgen Retrovirology Research BACKGROUND: A primary concern when targeting HIV-1 RNA by means of antisense related technologies is the accessibility of the targets. Using a library selection approach to define the most accessible sites for 20-mer oligonucleotides annealing within the highly structured 5'-UTR of the HIV-1 genome we have shown that there are at least four optimal targets available. RESULTS: The biological effect of antisense DNA and LNA oligonucleotides, DNA- and LNAzymes targeted to the four most accessible sites was tested for their abilities to block reverse transcription and dimerization of the HIV-1 RNA template in vitro, and to suppress HIV-1 production in cell culture. The neutralization of HIV-1 expression declined in the following order: antisense LNA > LNAzymes > DNAzymes and antisense DNA. The LNA modifications strongly enhanced the in vivo inhibitory activity of all the antisense constructs and some of the DNAzymes. Notably, two of the LNA modified antisense oligonucleotides inhibited HIV-1 production in cell culture very efficiently at concentration as low as 4 nM. CONCLUSION: LNAs targeted to experimentally selected binding sites can function as very potent inhibitors of HIV-1 expression in cell culture and may potentially be developed as antiviral drug in patients. BioMed Central 2007-04-26 /pmc/articles/PMC1866241/ /pubmed/17459171 http://dx.doi.org/10.1186/1742-4690-4-29 Text en Copyright © 2007 Jakobsen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jakobsen, Martin R
Haasnoot, Joost
Wengel, Jesper
Berkhout, Ben
Kjems, Jørgen
Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title_full Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title_fullStr Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title_full_unstemmed Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title_short Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites
title_sort efficient inhibition of hiv-1 expression by lna modified antisense oligonucleotides and dnazymes targeted to functionally selected binding sites
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1866241/
https://www.ncbi.nlm.nih.gov/pubmed/17459171
http://dx.doi.org/10.1186/1742-4690-4-29
work_keys_str_mv AT jakobsenmartinr efficientinhibitionofhiv1expressionbylnamodifiedantisenseoligonucleotidesanddnazymestargetedtofunctionallyselectedbindingsites
AT haasnootjoost efficientinhibitionofhiv1expressionbylnamodifiedantisenseoligonucleotidesanddnazymestargetedtofunctionallyselectedbindingsites
AT wengeljesper efficientinhibitionofhiv1expressionbylnamodifiedantisenseoligonucleotidesanddnazymestargetedtofunctionallyselectedbindingsites
AT berkhoutben efficientinhibitionofhiv1expressionbylnamodifiedantisenseoligonucleotidesanddnazymestargetedtofunctionallyselectedbindingsites
AT kjemsjørgen efficientinhibitionofhiv1expressionbylnamodifiedantisenseoligonucleotidesanddnazymestargetedtofunctionallyselectedbindingsites